ReviewThe World Allergy Organization journal2022

Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma.

Nicola A Hanania et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.